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Summary
Background Statins reduce LDL cholesterol and prevent vascular events, but their net eﬀ ects in people at low risk of 
vascular events remain uncertain.
Methods This meta-analysis included individual participant data from 22 trials of statin versus control (n=134 537; 
mean LDL cholesterol diﬀ erence 1·08 mmol/L; median follow-up 4·8 years) and ﬁ ve trials of more versus less statin 
(n=39 612; diﬀ erence 0·51 mmol/L; 5·1 years). Major vascular events were major coronary events (ie, non-fatal 
myocardial infarction or coronary death), strokes, or coronary revascularisations. Participants were separated into 
ﬁ ve categories of baseline 5-year major vascular event risk on control therapy (no statin or low-intensity statin) (<5%, 
≥5% to <10%, ≥10% to <20%, ≥20% to <30%, ≥30%); in each, the rate ratio (RR) per 1·0 mmol/L LDL cholesterol 
reduction was estimated.
Findings Reduction of LDL cholesterol with a statin reduced the risk of major vascular events (RR 0·79, 
95% CI 0·77–0·81, per 1·0 mmol/L reduction), largely irrespective of age, sex, baseline LDL cholesterol or previous 
vascular disease, and of vascular and all-cause mortality. The proportional reduction in major vascular events was at 
least as big in the two lowest risk categories as in the higher risk categories (RR per 1·0 mmol/L reduction from 
lowest to highest risk: 0·62 [99% CI 0·47–0·81], 0·69 [99% CI 0·60–0·79], 0·79 [99% CI 0·74–0·85], 0·81 [99% CI 
0·77–0·86], and 0·79 [99% CI 0·74–0·84]; trend p=0·04), which reﬂ ected signiﬁ cant reductions in these two lowest 
risk categories in major coronary events (RR 0·57, 99% CI 0·36–0·89, p=0·0012, and 0·61, 99% CI 0·50–0·74, 
p<0·0001) and in coronary revascularisations (RR 0·52, 99% CI 0·35–0·75, and 0·63, 99% CI 0·51–0·79; both 
p<0·0001). For stroke, the reduction in risk in participants with 5-year risk of major vascular events lower than 10% 
(RR per 1·0 mmol/L LDL cholesterol reduction 0·76, 99% CI 0·61–0·95, p=0·0012) was also similar to that seen in 
higher risk categories (trend p=0·3). In participants without a history of vascular disease, statins reduced the risks of 
vascular (RR per 1·0 mmol/L LDL cholesterol reduction 0·85, 95% CI 0·77–0·95) and all-cause mortality (RR 0·91, 
95% CI 0·85–0·97), and the proportional reductions were similar by baseline risk. There was no evidence that 
reduction of LDL cholesterol with a statin increased cancer incidence (RR per 1·0 mmol/L LDL cholesterol reduction 
1·00, 95% CI 0·96–1·04), cancer mortality (RR 0·99, 95% CI 0·93–1·06), or other non-vascular mortality.
Interpretation In individuals with 5-year risk of major vascular events lower than 10%, each 1 mmol/L reduction in 
LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years. This 
beneﬁ t greatly exceeds any known hazards of statin therapy. Under present guidelines, such individuals would not 
typically be regarded as suitable for LDL-lowering statin therapy. The present report suggests, therefore, that these 
guidelines might need to be reconsidered.
Funding British Heart Foundation; UK Medical Research Council; Cancer Research UK; European Community Biomed 
Programme; Australian National Health and Medical Research Council; National Heart Foundation, Australia.
Introduction
The Cholesterol Treatment Trialists’ (CTT) Collaboration 
previously reported meta-analyses of individual data 
from 170 000 individuals in 21 trials of standard statin 
regimens versus control and ﬁ ve trials of more intensive 
versus less intensive regimens.1 That report showed that 
lowering of LDL cholesterol by 1 mmol/L with a standard 
statin regimen reduced the incidence of major vascular 
events (deﬁ ned as non-fatal myocardial infarction or 
coronary death, any stroke, or coronary revascularisation 
procedure) by around a ﬁ fth, and that further reductions 
in LDL cholesterol with more intensive statin regimens 
yielded further reductions in risk. There was no evidence 
that lowering of LDL cholesterol increased the risk of 
non-vascular death or of cancer, even in participants with 
baseline LDL cholesterol less than 2 mmol/L (in whom 
LDL cholesterol was reduced from about 1·7 mmol/L 
[65 mg/dL] to 1·3 mmol/L [50 mg/dL]).2 
In those analyses, reduction of LDL cholesterol with a 
statin in participants with no previous history of 
vascular disease reduced the risk of major vascular 
events by about a ﬁ fth,1 but there remains uncertainty 
about whether statin therapy is of overall net beneﬁ t 
in primary prevention.3–5 This question is important 
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because, although individuals without previous vascular 
disease are at lower absolute risk, at least half of all 
vascular events occur among them.6 The availability of 
individual participant data from each trial within the 
CTT database (allowing the inclusion of information 
from both primary prevention trials and low-risk 
participants in other trials) allows a more complete 
assessment of the eﬀ ects of lowering of LDL cholesterol 
in low-risk people than was possible in previous meta-
analyses of published data.3,4 
Median predicted 
5-year MVE risk
Estimated 5-year MVE risk Total
<5% ≥5% to <10% ≥10% to <20%* ≥20% to <30% ≥30%
Statin vs control
MEGA† 2·7% 7247 (147) 925 (91) 42 (4) 0 (0) 0 (0) 8214 (242)
JUPITER 4·4% 11 212 (118) 6117 (162) 472 (19) 1 (0) 0 (0) 17 802 (299)
AFCAPS/ TexCAPS 5·2% 2944 (72) 3329 (225) 331 (47) 1 (0) 0 (0) 6605 (344)
ASCOT-LLA 8·1% 1505 (25) 5383 (229) 3168 (245) 234 (22) 15 (3) 10 305 (524)
WOSCOPS 9·2% 34 (0) 3848 (219) 2576 (293) 134 (36) 3 (2) 6595 (550)
GISSI-HF 9·6% 875 (34) 1523 (78) 1789 (171) 357 (52) 30 (11) 4574 (346)
ALERT 10·2% 286 (8) 740 (54) 705 (105) 237 (59) 134 (49) 2102 (275)
CARDS 10·9% 156 (0) 1043 (43) 1524 (144) 109 (16) 6 (1) 2838 (204)
ASPEN 13·6% 108 (0) 648 (13) 980 (99) 517 (90) 157 (48) 2410 (250)
ALLHAT-LLT 14·0% 92 (2) 2331 (144) 5468 (803) 1871 (438) 593 (183) 10 355 (1570)
Post-CABG 17·0% 0 (0) 24 (2) 1022 (128) 279 (44) 26 (5) 1351 (179)
GISSI-P 18·3% 0 (0) 14 (1) 2816 (272) 1268 (140) 173 (26) 4271 (439)
HPS 18·6% 320 (14) 2041 (134) 9424 (1267) 6722 (1488) 2029 (651) 20 536 (3554)
LIPID 22·1% 0 (0) 27 (3) 2946 (484) 5144 (1278) 897 (324) 9014 (2089)
PROSPER 22·4% 0 (0) 108 (13) 2208 (224) 1858 (293) 1630 (396) 5804 (926)
CORONA 23·2% 11 (1) 194 (16) 1463 (144) 2151 (292) 1192 (177) 5011 (630)
CARE 26·1% 0 (0) 0 (0) 362 (58) 2776 (615) 1021 (313) 4159 (986)
ALLIANCE 26·3% 0 (0) 0 (0) 288 (46) 1419 (298) 735 (203) 2442 (547)
LIPS 29·5% 0 (0) 0 (0) 118 (28) 770 (158) 789 (173) 1677 (359)
AURORA 31·7% 0 (0) 61 (8) 546 (85) 676 (136) 1490 (501) 2773 (730)
SSSS 33·1% 0 (0) 0 (0) 139 (13) 1159 (275) 3146 (1063) 4444 (1351)
4D 38·2% 0 (0) 6 (1) 117 (20) 273 (52) 859 (233) 1255 (306)
Subtotal, 22 trials 13·7% 24 790 (421) 28 362 (1436) 38 504 (4699) 27 956 (5782) 14 925 (4362) 134 537 (16 700)
More vs less statin
SEARCH 16·2% ·· ·· 9665 (1969) 2157 (680) 242 (104) 12 064 (2753)
A to Z 17·3% ·· ·· 3097 (307) 1191 (180) 209 (52) 4497 (539)
TNT 21·8% ·· ·· 3507 (520) 5078 (1075) 1416 (458) 10 001 (2053)
IDEAL 24·1% ·· ·· 1754 (326) 5257 (1125) 1877 (593) 8888 (2044)
PROVE-IT 33·8% ·· ·· 27 (3) 1125 (185) 3010 (676) 4162 (864)
Subtotal, ﬁ ve trials 20·8% ·· ·· 18 050 (3125) 14 808 (3245) 6754 (1883) 39 612 (8253)
Data are median risk or number of participants (number of ﬁ rst major vascular events). Studies are shown in order of increasing median predicted 5-year MVE risk. The 
predicted risk for the trials of more versus less statin is that under the less intensive statin regimen. We imputed missing data for age, sex, treatment for hypertension, lipids, 
and blood pressure at baseline for the purpose of predicting 5-year MVE risk and for risk stratiﬁ cation. MEGA=Management of Elevated Cholesterol in the Primary Prevention 
Group of Adult Japanese. JUPITER=Justiﬁ cation for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin. AFCAPS/TexCAPS=Air Force/Texas Coronary 
Atherosclerosis Prevention Study. ASCOT-LLA=Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm. WOSCOPS=West of Scotland Coronary Prevention Study. 
GISSI-HF=Gruppo Italiano per lo Studio della Sopravvivenza nell’Insuﬃ  cienza cardiaca. ALERT=Assessment of Lescol in Renal Transplantation. CARDS=Collaborative 
Atorvastatin Diabetes Study. ASPEN=Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus. 
ALLHAT-LLT=Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Post-CABG=Post-Coronary Artery Bypass Graft. GISSI-P=Gruppo Italiano per lo 
Studio della Sopravvivenza nell’Infarto Miocardico. HPS=Heart Protection Study. LIPID=Long-term Intervention with Pravastatin in Ischaemic Disease. PROSPER=PROspective 
Study of Pravastatin in the Elderly at Risk. CORONA=Controlled Rosuvastatin Multinational Trial in Heart Failure. CARE=Cholesterol And Recurrent Events. 
ALLIANCE=Aggressive Lipid-Lowering Initiation Abates New Cardiac Events. LIPS=Lescol Intervention Prevention Study. AURORA=A Study to Evaluate the Use of Rosuvastatin 
in Subjects on Regular Hemodialysis: an Assessment of Survival and Cardiovascular Events. SSSS=Scandinavian Simvastatin Survival Study. 4D=Die Deutsche Diabetes Dialyse 
Studie. SEARCH=Study of the Eﬀ ectiveness of Additional Reductions in Cholesterol and Homocysteine. A to Z=Aggrastat to Zocor. TNT=Treating to New Targets. 
IDEAL=Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. PROVE-IT=Pravastatin or Atorvastatin Evaluation and Infection Therapy. 
*For trials of more versus less statin, this category includes 141 participants (48 [4 MVEs] from A to Z and 93 [11 MVEs] from SEARCH) with an estimated 5-year risk of MVE 
between 5% and 10%. †Includes 382 patients who were excluded from the original publication.  
Table 1: Numbers of participants and number of ﬁ rst major vascular events (MVEs) in each study contributing to vascular disease risk categories 
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Methods
Trials
The methods of the CTT collaboration have been 
described in detail elsewhere.1,7,8 In the present analyses, 
a trial was eligible if it reported by the end of 2009 and 
provided data before June, 2011, and met three criteria: 
(1) it included at least one intervention whose main 
eﬀ ect was to lower LDL cholesterol concentration; (2) it 
was unconfounded with respect to this intervention (ie, 
no other diﬀ erences in risk factor modiﬁ cation between 
the treatment groups were intended); and (3) it 
recruited at least 1000 participants with scheduled 
treatment duration of at least 2 years. The main 
outcomes of interest were major vascular events, major 
coronary events (deﬁ ned as non-fatal myocardial 
infarction or coronary death), stroke (subdivided by 
type), coronary revascularisation pro cedures, cancers, 
and cause-speciﬁ c mortality. 
Statistical analysis
Two diﬀ erent Cox proportional hazards models were 
developed to allow risk to be modelled separately in trials 
of statin versus control (22 trials; model 1) and in trials 
of more versus less intensive statin regimens (ﬁ ve trials; 
model 2). Both models incorporated terms derived from 
characteristics measured at the time of randomisation, 
terms that modelled average diﬀ erences in risk between 
trials (as well as within speciﬁ c periods of time within 
each trial), and interaction terms (appendix pp 1–2). On 
the basis of these risk prediction models, participants in 
both treatment groups of each study were assigned to 
one of ﬁ ve baseline categories of 5-year risk of a major 
vascular event: <5%; ≥5% to <10%; ≥10% to <20%; ≥20% 
to <30%; or ≥30%. Further details of model development 
are shown in the appendix pp 15–16. 
Analyses included all participants who were randomly 
assigned to treatment groups, irrespective of whether 
they received their allocated treatment (ie, intention-to-
treat). Analyses of the eﬀ ects on disease rates within each 
trial are derived from the logrank (o–e) statistic and its 
variance (v) for ﬁ rst events. Meta-analyses were weighted 
by the absolute LDL cholesterol diﬀ erence in that trial at 
1 year (d mmol/L), and are reported as eﬀ ects per 
1·0 mmol/L reduction in LDL cholesterol. In a meta-
analysis of several trials, the log of the rate ratio (RR) per 
1·0 mmol/L was calculated as S/V with variance 1/V (and 
hence, for example, with 95% CI of S/V±1·96/√V), where 
S is the sum over all trials of d(o–e) and V is the sum over 
all trials of d²v. For most subgroup analyses, the weight 
for a particular subgroup was the LDL cholesterol 
diﬀ erence observed in the whole trial, but analyses by 
baseline LDL cholesterol concentration used LDL weights 
speciﬁ c to a particular subgroup of a particular trial.1 In 
trials comparing more versus less intensive statin therapy, 
the relevant baseline lipid values were those achieved on 
the less intensive regimen. In three of these trials,9–11 
however, any statin therapy was stopped before random-
isation, so we estimated their relevant baseline values by 
multiplying the values at the randomisation visit (ie, oﬀ  
statin treatment) by the mean proportional reduction 
Number of 
participants
Observed 
annual MVE 
rate in those 
allocated  
control or 
less statin
Observed 
annual MCE 
rate in those 
allocated 
control or 
less statin
Median 
follow-up 
in survivors 
(years)*
Women (%) Mean age 
(SD; years)
Baseline 
LDL 
cholesterol 
(mmol/L)* 
Diabetes (%) Baseline history of vascular disease (%)
Previous CHD Other vascular† None‡
Statin vs control
<5% 24 790 0·6% 0·2% 4·0 54% 59 (8) 3·43 7% 0% 4% 96%
≥5% to <10% 28 362 1·6% 0·8% 4·3 27% 61 (9) 3·68 18% 2% 11% 87%
≥10% to <20% 38 504 3·4% 1·5% 4·7 29% 64 (9) 3·61 24% 43% 22% 44%
≥20% to <30% 27 956 5·7% 2·6% 5·0 16% 65 (9) 3·72 19% 80% 28% 13%
≥30% 14 925 9·5% 5·1% 4·9 14% 66 (9) 3·92 44% 86% 39% 7%
Subtotal, 22 trials 134 537 3·6% 1·8% 4·8 29% 63 (9) 3·70 21% 39% 20% 52%
More vs less statin§
≥10% to <20%¶ 18 050 3·7% 1·6% 5·9 22% 60 (10) 2·37 4% 100% 1% 0%
≥20% to <30% 14 808 5·9% 2·4% 5·2 17% 62 (9) 2·59 17% 100% 12% 0%
≥30% 6754 10·7% 4·2% 2·4 18% 64 (10) 2·81 35% 100% 35% 0%
Subtotal , ﬁ ve trials 39 612 5·3% 2·2% 5·1 19% 62 (10) 2·53 14% 100% 11% 0%
CHD=coronary heart disease. MCE=major coronary event. *Estimated using standard Kaplan-Meier methods with participants censored at their date of death; median follow-up and baseline LDL cholesterol for 
trial subgroups weighted by trial subgroup-speciﬁ c variances of observed logrank (o–e) for major vascular events. †History of intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, 
peripheral artery disease or heart failure (if known). ‡No known history of CHD or other vascular disease. §The estimated 5-year major vascular event risk is with the less intensive statin regimen and observed 
MVE and MCE rates are for participants allocated the less intensive statin regimen; in three more versus less statin trials (A to Z, PROVE-IT, and IDEAL) there was no active run-in period before randomisation and 
so for the purpose of risk stratiﬁ cation and presentation of results the LDL cholesterol at baseline for the participants in these trials was adjusted for the observed LDL cholesterol reduction from baseline to year 1 
in those allocated low intensity statin in the respective trial. ¶Includes 141 participants (48 [4 MVEs] from A to Z and 93 [11 MVEs] from SEARCH) with an estimated 5-year risk of MVE between 5% and 10%.
Table 2: Baseline characteristics of participants, by predicted 5-year risk of a major vascular event (MVE)
See Online for appendix
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observed at 1 year in participants allocated the less 
intensive regimen.1 Proportional risk reductions in 
diﬀ erent subgroups were compared by standard χ² tests 
for heterogeneity or, where appropriate, trend. To allow 
for multiple testing by subdivisions, only overall summary 
rate ratios have 95% CIs; all other rate ratios have 
99% CIs. Analyses used SAS version 9.1 (SAS Institute, 
Cary, NC, USA), Stata version 11.2 (StataCorp, TX, USA), 
and R version 2.11.1.
Role of the funding sources
The funding sources had no involvement in the study 
design, data collection, analysis and interpretation, the 
writing of the report, or the decision to submit for 
publication. The writing committee had full access to all 
data and accepts full responsibility for the content of 
this report.
Results 
Individual participant data were available from 27 trials 
in 174 149 participants. 22 trials compared a standard 
statin regimen versus control (134 537 participants; mean 
baseline LDL cholesterol 3·70 [SD 0·7] mmol/L; mean 
diﬀ erence at 1 year 1·08 mmol/L; median follow-up 
duration in survivors 4·8 years)12–33 and ﬁ ve trials assessed 
a more intensive versus a less intensive statin regimen 
(39 612 participants; mean baseline LDL cholesterol 
2·53 [SD 0·6] mmol/L; mean diﬀ erence at 1 year 
0·51 mmol/L; median follow-up duration in survivors 
5·1 years).9–11,34,35 Individual participant data were unavail-
able from only two eligible trials in 6331 higher-risk 
patients with pre-existing vascular disease (SPARCL36 
and GREACE37).
The baseline prognostic factors that were strong 
predictors of major vascular event risk (ie, at the 1% 
signiﬁ cance level) were broadly similar in the trials of 
statin versus control and the trials of more versus less 
intensive statin regimens (appendix pp 1–2). Predicted 
risk compared well with observed risk for each trial, as 
well as within each 5-year risk group (appendix p 3). 
When trials were ordered by their median 5-year 
predicted risk of a major vascular event, the ﬁ ve trials 
with the lowest median predicted risks (all <10%) were 
primary prevention trials (table 1).13,15,22,29,31 By contrast, 
almost all participants with predicted 5-year risk of 20% 
or higher were recruited into trials in patients with a 
deﬁ nite history of vascular disease.12,14,16–19,25,28 The 
predicted 5-year risk of a major vascular event was also 
20% or higher in most dialysis patients.26,30 In two trials 
in patients with heart failure,32,33 there was a high risk of 
sudden death, but such deaths were categorised 
diﬀ erently, with a much smaller proportion of such 
deaths thought to be due to coronary occlusion in the 
GISSI-HF trial33 than in CORONA;32 this diﬀ erence is 
the main reason why the predicted 5-year risk of major 
vascular events was more than twice as high in CORONA 
(23%) as in GISSI-HF (10%).
Among the 22 trials of statin versus control, the 
observed annual major vascular event rate ranged from 
0·6% in the lowest predicted risk category to 9·5% in the 
highest risk category, whereas in trials of more versus 
less intensive statin therapy (which were undertaken 
solely in patients with previous coronary disease) the 
observed annual event rate varied between 3·7% and 
10·7% across the categories studied (table 2). In both sets 
of trials, the achieved reduction in LDL cholesterol at 
1 year with statin therapy or more intensive statin therapy 
was greater in people with higher predicted 5-year risk of 
major vascular events (appendix p 4). 
Among all 27 trials, statins reduced the risk of major 
vascular events by 21% per 1·0 mmol/L LDL cholesterol 
reduction (RR 0·79, 95% CI 0·77–0·81, p<0·0001), with 
separately signiﬁ cant proportional reductions in each 
risk group (ﬁ gure 1). In particular, there were signiﬁ cant 
reductions in major vascular event risk in each of the two 
Major coronary event
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Overall 
 50 (0·11)
 276 (0·50)
 1644 (1·29)
 1789 (1·93)
 1471 (3·73)
 5230 (1·45)
 88 (0·19)
 435 (0·79)
 1973 (1·57)
 2282 (2·49)
 1887 (4·86)
 6665 (1·87)
 0·57 (0·36–0·89)
 0·61 (0·50–0·74)
 0·77 (0·69–0·85)
 0·77 (0·71–0·83)
 0·78 (0·72–0·84)
 0·76 (0·73–0·79)
p<0·0001
Events (% per annum) RR (CI) per 1·0 mmol/L reduction
in LDL cholesterol
Trend test
Statin/more Control/less
5-year MVE risk
at baseline
χ2=5·66
(p=0·02)
1
χ2=1·03
(p=0·3)
1
χ2=4·93
(p=0·03)
1
χ2=4·29
(p=0·04)
1
Any stroke 
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30% 
≥30%
Overall 
 71 (0·16)
 190 (0·34)
 797 (0·62)
 781 (0·84)
 571 (1·45)
 2410 (0·67) 
 90 (0·20)
 240 (0·43)
 907 (0·71)
 900 (0·97)
 661 (1·68)
 2798 (0·78)
 0·74 (0·46–1·19) 
 0·77 (0·60–0·98) 
 0·86 (0·75–0·98) 
 0·86 (0·75–0·97) 
 0·86 (0·75–0·99) 
 0·85 (0·80–0·89)
p<0·0001
 
Coronary revascularisation 
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Overall 
 73 (0·16) 
 224 (0·40)
 1706 (1·36)
 2206 (2·46)
 1260 (3·28)
 5469 (1·55)
 0·52 (0·35–0·75) 
 0·63 (0·51–0·79) 
 0·75 (0·67–0·83) 
 0·79 (0·73–0·86) 
 0·76 (0·69–0·83) 
 0·76 (0·73–0·79)
p<0·0001 
 135 (0·30)
 342 (0·62) 
 2061 (1·67)
 2717 (3·08)
 1655 (4·40)
 6910 (1·98) 
Major vascular event 
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Overall
 167 (0·38)
 604 (1·10)
 3614 (2·96)
 4108 (4·74)
 2787 (7·64)
 11 280 (3·27)
 0·62 (0·47–0·81) 
 0·69 (0·60–0·79) 
 0·79 (0·74–0·85) 
 0·81 (0·77–0·86) 
 0·79 (0·74–0·84) 
 0·79 (0·77–0·81)
p<0·0001 
 254 (0·56)
 847 (1·57)
 4195 (3·50) 
 4919 (5·80)
 3458 (9·82)
 13 673 (4·04)
0·50 0·75 1 1·25 1·50
Statin/more better Control/less better
99% limits 95% limits
Figure 1: Eﬀ ects on major coronary events, strokes, coronary revascularisation procedures, and major 
vascular events per 1·0 mmol/L reduction in LDL cholesterol at diﬀ erent levels of risk
MVE=major vascular event. RR=rate ratio. CI=conﬁ dence interval.
For more on R see 
www.R-project.org
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lowest risk categories (RR per 1·0 mmol/L LDL 
cholesterol reduction 0·62, 99% CI 0·47–0·81, for 5-year 
predicted risk <5%, and 0·69, 99% CI 0·60–0·79, for 
5-year predicted risk ≥5% to <10%; both p<0·0001; 
ﬁ gure 1). These results were qualitatively similar after 
exclusion of ﬁ ve trials12,15,22,24,31 that ended early on the 
advice of their data monitoring committees (data not 
shown). The proportional reductions in major vascular 
events per 1·0 mmol/L LDL cholesterol reduction in the 
two lowest risk categories seemed to be at least as large 
as for other participants (ﬁ gure 1), even after further 
stratiﬁ cation by age and sex (appendix p 6) or by baseline 
LDL cholesterol (appendix p 7).
The reductions in risk of major vascular events among 
the two categories of participant at lowest risk reﬂ ected 
reductions in major coronary events (RR per 1·0 mmol/L 
LDL cholesterol reduction 0·57, 99% CI 0·36–0·89, 
p=0·0012, and 0·61, 99% CI 0·50–0·74, p<0·0001), 
mainly non-fatal myocardial infarction, and in coronary 
revascularisations (RR 0·52, 99% CI 0·35–0·75, and 
0·63, 99% CI 0·51–0·79; both p<0·0001), that were at 
least as large as those seen in higher risk participants 
(trend p=0·02 for major coronary events and p=0·03 for 
coronary revascularisations; ﬁ gure 1, appendix p 8). The 
reduction in stroke risk per 1·0 mmol/L LDL cholesterol 
reduction (RR 0·85, 95% CI 0·80–0·89) was similar at all 
levels of baseline major vascular event risk (trend p=0·3; 
ﬁ gure 1). In particular, the reduction in stroke risk in 
those with predicted 5-year major vascular event risk 
lower than 10% (ie, the two lowest risk groups combined; 
RR 0·76, 99% CI 0·61–0·95; p=0·0012) was similar to 
that seen in higher risk categories. The proportional 
reductions in ischaemic stroke (RR per 1·0 mmol/L LDL 
cholesterol reduction 0·79, 95% CI 0·74–0·85) and in 
strokes of unknown cause (RR 0·87, 95% CI 0·79–0·97) 
were similar irrespective of baseline major vascular event 
risk, and there was no evidence that the RR for 
haemorrhagic stroke (1·15, 95% CI 0·97–1·38) varied by 
baseline risk (appendix p 9). Separate analyses of major 
vascular events and its components in the trials that 
tested statin versus control and the trials that tested more 
versus less intensive statin regimens are shown in the 
appendix pp 10–11. 
For participants with previous vascular disease, the 
proportional reductions in major vascular event risk 
were broadly similar irrespective of predicted risk of 
these events (ﬁ gure 2). In participants with no history of 
vascular disease, the proportional reduction in major 
vascular events was at least as large in the two lowest risk 
groups (RR per 1·0 mmol/L LDL reduction 0·61, 99% CI 
0·45–0·81, and 0·66, 99% CI 0·57–0·77) as in those at 
higher risk. Further exclusion from these lowest risk 
groups of participants with diabetes or chronic kidney 
disease had little eﬀ ect on the proportional reductions in 
major vascular events (RR per 1·0 mmol/L LDL 
cholesterol reduction 0·63, 99% CI 0·46–0·85, for 5-year 
predicted risk <5%; 0·64, 99% CI 0·54–0·76, for 5-year 
predicted risk ≥5% to <10%). The LDL-weighted 
proportional reduction in major coronary events in par-
ticipants with no history of vascular disease was also at 
least as large in the two lowest risk groups as in those at 
higher risk (appendix p 12).
In all participants, there was a proportional reduction 
in vascular mortality of 12% per 1·0 mmol/L LDL 
cholesterol reduction (RR 0·88, 95% CI 0·84–0·91; 
ﬁ gure 3), which was chieﬂ y attributable to reductions in 
coronary deaths of 20% (RR 0·80, 95% CI 0·76–0·85) 
and in other cardiac deaths of 8% (RR 0·92, 95% CI 
0·87–0·98; appendix p 13). There were too few deaths 
among the lower risk participants to allow reliable direct 
assessment of the eﬀ ects of statin therapy (appendix 
p 13). However, the LDL-weighted proportional reduc-
tions seemed similar in each risk category both for the 
aggregate of all vascular deaths (trend p=0·7; ﬁ gure 3) 
and for each speciﬁ c cause of vascular death (all trend 
p=NS; appendix p 13), and there was no signiﬁ cant trend 
towards an increase in non-vascular mortality in those at 
lower risk (trend p=0·9; ﬁ gure 3). In participants with 
no history of vascular disease, reduction of LDL 
cholesterol with statin therapy reduced the risk of 
Participants with vascular disease
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Subtotal 
 148 (0·35)
 487 (1·02)
 854 (2·52)
 294 (4·40)
 121 (7·29)
 1904 (1·44)
 19 (0·87)
 117 (1·56)
 2760 (3·13)
 3814 (4·77)
 2666 (7·66)
 9376 (4·41)
 167 (0·38)
 604 (1·10)
 3614 (2·96)
 4108 (4·74)
 2787 (7·64)
 11 280 (3·27)
Participants without vascular disease
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Subtotal 
All participants
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Overall
Heterogeneity between participants without
and with vascular disease: χ2=2·74 (p=0·10)
Events (% per annum) Trend test
Statin/more Control/less
5-year MVE
risk at 
baseline
χ2=9·10
(p=0·003)
1
χ2=0·01
(p=0·9)
1
χ2=4·29
(p=0·04)
1
99% limits 95% limits 0·50 0·75 1 1·25 1·50
Statin/more better Control/less better
1
 229 (0·53)
 716 (1·53)
 1003 (2·98)
 351 (5·28)
 126 (8·16)
 2425 (1·84)
 25 (1·18)
 131 (1·80)
 3192 (3·71)
 4568 (5·85)
 3332 (9·90)
 11 248 (5·43)
 254 (0·56)
 847 (1·57)
 4195 (3·50)
 4919 (5·80)
 3458 (9·82)
 13 673 (4·04)
 0·61 (0·45–0·81)
 0·66 (0·57–0·77)
 0·82 (0·72–0·93)
 0·81 (0·65–1·01)
 0·83 (0·58–1·18)
 0·75 (0·70–0·80)
p<0·0001
 0·73 (0·33–1·61)
 0·84 (0·62–1·14)
 0·78 (0·72–0·85)
 0·81 (0·76–0·86)
 0·79 (0·74–0·84)
 0·80 (0·77–0·82)
p<0·0001
 0·62 (0·47–0·81)
 0·69 (0·60–0·79)
 0·79 (0·74–0·85)
 0·81 (0·77–0·86)
 0·79 (0·74–0·84)
 0·79 (0·77–0·81)
p<0·0001
RR (CI) per 1·0 mmol/L reduction
in LDL cholesterol
Figure 2: Eﬀ ects on major vascular events per 1·0 mmol/L reduction in LDL cholesterol at diﬀ erent levels of 
risk, by history of vascular disease 
MVE=major vascular event. RR=rate ratio. CI=conﬁ dence interval.
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vascular mortality (RR per 1·0 mmol/L reduction 0·85, 
95% CI 0·77–0·95, p=0·004; ﬁ gure 3) and, since there 
was no increase in the risk of non-vascular causes of 
death (RR 0·97, 95% CI 0·88–1·07; ﬁ gure 3), reduced 
the risk of all-cause mortality (RR 0·91, 95% CI 
0·85–0·97, p=0·007; appendix p 14). These mortality 
beneﬁ ts remained even after further exclusion of 
participants with diabetes or chronic kidney disease at 
baseline (vascular death, RR 0·80, 95% CI 0·67–0·95; 
any death, 0·87, 95% CI 0·78–0·95). There was no 
evidence of an increase in cancer incidence (RR per 
1·0 mmol/L LDL reduction 1·00, 95% CI 0·96–1·04) or 
of cancer death (RR 0·99, 95% CI 0·93–1·06) at any level 
of major vascular event risk (ﬁ gure 4).
Discussion
The most recent CTT meta-analysis of individual 
participant data from randomised trials showed that 
lowering of LDL cholesterol with standard statin 
regimens safely reduced the 5-year incidence of major 
coronary events, coronary revascularisations, and 
ischaemic strokes by about one ﬁ fth per 1·0 mmol/L 
reduction in LDL cholesterol, and that additional 
reductions in LDL cholesterol obtained with more 
intensive statin regimens further reduced the incidence 
of these major vascular events.1 The present results show 
that reduction of LDL cholesterol with statin therapy 
signiﬁ cantly reduced the risk of major vascular events in 
individuals with 5-year risk lower than 10% (in whom 
the mean risks were 2·6% for major coronary events 
plus 3% for other major vascular events), even in those 
with no previous history of vascular disease, diabetes, or 
chronic kidney disease (panel). 
The estimated absolute reduction in major vascular 
events in participants with 5-year risk of these events 
lower than 10% was around 11 per 1000 over 5 years for 
each 1·0 mmol/L reduction in LDL cholesterol (4·1% 
statin or more intensive statin regimen vs 5·2% control 
or less intensive regimen). Modern statin regimens, 
however, can often reduce LDL cholesterol by more than 
1 mmol/L,38,39 which would yield even larger absolute 
reductions in major vascular events. The avoidance of 
life-threatening or potentially disabling events in 
apparently healthy low-risk people might be deemed 
worthwhile provided that they are not accompanied by 
any deﬁ nite hazard that is of comparable severity. 
Although there was no evidence of any increased risk of 
death from non-vascular causes or of cancer in those at 
low risk (which is consistent with previous detailed 
analyses of the eﬀ ect of statins on cancer2), several known 
Any vascular death
Participants without vascular disease
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Subtotal
Events (% per annum) RR (CI) per 1·0 mmol/L reduction
in LDL cholesterol
Trend test
Statin/more Control/less
5-year MVE
risk at 
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(p=0·2)
1
χ2=1·49
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1
χ2=0·18
(p=0·7)
1
χ2=0·47
(p=0·5)
1
χ2=0·04
(p=0·8)
1
χ2=0·02
(p=0·9)
1
99% limits 95% limits 0·50 0·75 1 1·25 1·50
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Participants with vascular disease
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Subtotal
All participants
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Overall
Heterogeneity between participants without
and with vascular disease: χ2=0·28 (p=0·6)1
Non-vascular death
Participants without vascular disease
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Subtotal
Participants with vascular disease
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Subtotal
All participants
<5%
≥5% to <10%
≥10% to <20%
≥20% to <30%
≥30%
Overall
Heterogeneity between participants without
and with vascular disease: χ2=0·07 (p=0·8)1
 31 (0·07)
 117 (0·24)
 307 (0·87)
 164 (2·32)
 93 (5·21)
 712 (0·53)
 40 (0·09)
 153 (0·32)
 342 (0·96)
 168 (2·34)
 98 (5·84)
 801 (0·59)
0·80 (0·43–1·47)
0·75 (0·55–1·04)
0·84 (0·67–1·05)
0·97 (0·72–1·32)
0·88 (0·59–1·33)
0·85 (0·77–0·95)
p=0·004
 48 (2·16)
 193 (2·52)
 1166 (1·24)
 1432 (1·61)
 1247 (3·14)
 4086 (1·76)
 52 (2·40)
 177 (2·35)
 1249 (1·34)
 1665 (1·89)
 1435 (3·60)
 4578 (1·98)
0·93 (0·53–1·62)
1·07 (0·81–1·41)
0·89 (0·79–1·00)
0·87 (0·80–0·95)
0·87 (0·79–0·95)
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p<0·0001
 79 (0·18)
 310 (0·55)
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 1596 (1·67)
 1340 (3·23)
 4798 (1·30)
 92 (0·20)
 330 (0·59)
 1591 (1·23)
 1833 (1·92)
 1533 (3·69)
 5379 (1·47)
0·87 (0·58–1·31)
0·92 (0·74–1·13)
0·88 (0·79–0·97)
0·88 (0·81–0·96)
0·87 (0·80–0·95)
0·88 (0·84–0·91)
p<0·0001
 98 (0·23)
 205 (0·42)
 352 (0·99)
 169 (2·39)
 79 (4·43)
 903 (0·67)
 87 (0·20)
 238 (0·49)
 377 (1·06)
 148 (2·07)
 71 (4·23)
 921 (0·68)
1·13 (0·76–1·69)
0·87 (0·67–1·11)
0·94 (0·76–1·15)
1·13 (0·81–1·57)
1·07 (0·68–1·69)
0·97 (0·88–1·07)
p=0·60
 18 (0·81)
 65 (0·85)
 702 (0·74)
 794 (0·90)
 602 (1·52)
 2181 (0·94)
 14 (0·65)
 71 (0·94)
 727 (0·78)
 793 (0·90)
 634 (1·59)
 2239 (0·97)
1·38 (0·53–3·63)
0·92 (0·61–1·41)
0·95 (0·81–1·11)
0·98 (0·86–1·12)
0·95 (0·82–1·09)
0·96 (0·90–1·02)
p=0·18
 116 (0·26)
 270 (0·48)
 1054 (0·81)
 963 (1·01)
 681 (1·64)
 3084 (0·84)
 101 (0·22)
 309 (0·55)
 1104 (0·86)
 941 (0·99)
 705 (1·70)
 3160 (0·86)
1·16 (0·80–1·68)
0·88 (0·71–1·09)
0·94 (0·83–1·07)
1·00 (0·89–1·13)
0·96 (0·83–1·10)
0·96 (0·92–1·01)
p=0·16
Figure 3: Eﬀ ects on vascular and non-vascular deaths per 1·0 mmol/L reduction 
in LDL cholesterol at diﬀ erent levels of risk, by history of vascular disease
MVE=major vascular event. RR=rate ratio. CI=conﬁ dence interval. There were a 
further 179 (statin/more statin) versus 210 (control/less statin) deaths of 
unknown cause among participants without vascular disease and 309 (statin/
more statin) versus 338 (control/less statin) deaths of unknown cause among 
participants with vascular disease.
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or potential hazards of statin therapy need to be 
considered when estimating the net eﬀ ects of statin 
therapy in people at lowest risk.
First, statin therapy is associated with a small increased 
risk of myopathy (excess incidence of about 0·5 per 1000 
over 5 years) and, more rarely, of rhabdomyolysis (excess 
incidence of about 0·1 per 1000 over 5 years).38 The risks 
of myopathy are dose-related but, with the exception of 
simvastatin 80 mg daily (or lower doses in Asian 
populations), intensive statin regimens have not been 
shown to result in substantial myopathy risks.38 Second, 
the most recent CTT report raised the possibility that 
statin therapy might increase the risk of haemorrhagic 
stroke.1 The present analyses suggest that the annual 
excess risk of haemorrhagic strokes per 1·0 mmol/L LDL 
cholesterol reduction might be of the order of 0·5 per 
1000 people treated over 5 years (appendix p 9), although 
it might be higher in populations in which haemorrhagic 
stroke accounts for a higher proportion of strokes (eg, 
Asian populations40). But, since statin therapy produced a 
clear reduction in overall stroke that was independent of 
predicted risk, such an increase in haemorrhagic stroke 
risk would typically be outweighed by the reduction in 
the risk of ischaemic stroke (as well as the reduction in 
other occlusive vascular events and deaths) even in 
individuals whose 5-year risk of major vascular events is 
lower than 5%. Third, recent meta-analyses have 
suggested that statin therapy might be associated with a 
proportional increase in the diagnosis of diabetes 
mellitus of about 10%41 and that more intensive statin 
therapy produces a bigger increase.42 The observed 
incidence of diabetes recorded in the primary prevention 
trials was about 5% over 5 years, so the absolute excess 
was about 0·1% per year.41 If new diagnoses of diabetes 
were associated with an immediate doubling in 
cardiovascular risk43 in individuals with 5-year risk of 
major vascular events lower than 10%, then the expected 
eﬀ ect would be only about 0·2 fewer events avoided per 
1000 individuals treated over 5 years. Such an eﬀ ect is 
more than 50-times smaller than the absolute beneﬁ t 
observed with statin therapy in such individuals (about 
11 fewer major vascular events per 1000 treated over 
5 years per 1·0 mmol/L reduction in LDL cholesterol; see 
ﬁ gure 5 for absolute beneﬁ ts corresponding to particular 
reductions in LDL cholesterol in individuals at diﬀ erent 
levels of major vascular event risk). Moreover, long-term 
follow-up of statin trials has shown that the absolute 
reductions in major vascular events increase while the 
statin treatment is continued1 and that these beneﬁ ts 
persist for at least 5 years after the treatment has stopped, 
with no evidence of any adverse eﬀ ects emerging with 
extended follow-up.44–47 These ﬁ ndings would suggest 
that any long-term eﬀ ects of any small excesses in 
haemorrhagic strokes and in diagnoses of diabetes are 
not associated with long-term eﬀ ects on major vascular 
events that are suﬃ  ciently large to outweigh the 
persistent beneﬁ ts of statin therapy.
The observed event rates shown in the ﬁ gures for 
each risk category can be readily compared with risk 
thresholds used in treatment guidelines. For example, 
under present guidelines, including those of the Adult 
Treatment Panel III,48,49 the Fourth Joint Task Force of 
the European Society of Cardiology,50 the Task Force for 
the manage ment of dyslipidaemias of the European 
Society of Cardiology and the European Atherosclerosis 
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1
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 324 (0·73)
 605 (1·10)
 1804 (1·42)
 1667 (1·79)
 821 (2·04)
 5221 (1·45)
 315 (0·70)
 663 (1·21)
 1827 (1·45)
 1628 (1·76)
 777 (1·92)
 5210 (1·45)
1·05 (0·85–1·31)
0·91 (0·78–1·05)
1·00 (0·91–1·10)
1·02 (0·93–1·12)
1·02 (0·90–1·16)
1·00 (0·96–1·04)
 p=0·99
 64 (0·14)
 171 (0·30)
 697 (0·54)
 609 (0·64)
 293 (0·71)
 1834 (0·50)
 57 (0·13)
 186 (0·33)
 718 (0·56)
 584 (0·61)
 304 (0·73)
 1849 (0·50)
1·14 (0·69–1·89)
0·93 (0·71–1·23)
1·00 (0·86–1·16)
1·02 (0·88–1·19)
0·97 (0·80–1·19)
0·99 (0·93–1·06)
 p=0·86
Figure 4: Eﬀ ects on cancer incidence and cancer mortality per 1·0 mmol/L reduction in LDL cholesterol at 
diﬀ erent levels of risk
MVE=major vascular event. RR=rate ratio. CI=conﬁ dence interval.
Panel: Research in context
Systematic review
Lowering of LDL cholesterol with a statin reduces the risk of 
myocardial infarction, coronary death, ischaemic stroke, and 
coronary revascularisation by about one ﬁ fth per 1 mmol/L 
LDL cholesterol reduction in a wide range of people.1 
However, tabular meta-analyses of people at low risk of these 
events, studied predominantly in primary prevention trials, 
have concluded that statin therapy might not result in 
worthwhile net beneﬁ t in this group.3,4
Interpretation
Individual participant data in the Cholesterol Treatment 
Trialists’ Collaboration of 27 trials involving 
175 000 participants showed that statin therapy reduces the 
risk of major vascular events (non-fatal myocardial 
infarction, coronary death, coronary revascularisation, or 
stroke) in people with 5-year risk of such an event lower than 
10% (and, separately, in those at 5-year risk <5%), and in 
these people each 1·0 mmol/L reduction in LDL cholesterol 
produces 11 fewer major vascular events per 1000 treated 
over 5 years, a beneﬁ t that greatly exceeds any known 
hazards of statin therapy.
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Society,51 and the UK National Institute of Clinical 
Excellence,52 people with 5-year risk of major vascular 
events lower than 10% (ie, the lowest two categories of 
risk in these analyses) would typically not be judged 
suitable for statin treatment (table 3, appendix p 5). 
Judgments about the appropriateness of widespread 
prescription of statins for the primary prevention of 
vascular events in patients at lower risk also depend on 
the cost eﬀ ectiveness of such a strategy, which in turn 
depends on the local availability and cost of therapy. 
Generic statin interventions, if eﬀ ective, are likely to be 
cost-eﬀ ective in individuals at annual vascular disease 
risk down to at least about 1%.53–55 The present report 
shows that statins are indeed both eﬀ ective and safe for 
people with 5-year risk of major vascular events lower 
than 10% and, therefore, suggests that these guidelines 
might need to be reconsidered.
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Figure 5: Predicted 5-year beneﬁ ts of LDL cholesterol reductions with statin treatment at diﬀ erent levels of risk
(A) Major vascular events and (B) vascular deaths. Lifetable estimates using major vascular event risk or vascular 
death risk in the respective risk categories and overall treatment eﬀ ects per 1·0 mmol/L reduction in LDL 
cholesterol with statin. 
Observed 
MCE 
event rate 
(% per 
annum)*
Observed 
vascular 
death rate 
(% per 
annum)*
Broad eligibility under 
current guidelines
ATP-III† ESC task 
force‡
NICE§
CTT risk category
<5% 0·2 0·1 × × ×
≥5% to <10% 0·8 0·3 × × ×
≥10% to <20% 1·6 1·0 3 3 3
≥20% to <30% 3·2 2·3 3 3 3
≥30% 5·6 5·8 3 3 3
CTT=Cholesterol Treatment Trialists’. MCE=major coronary event. *Among 
control-allocated participants without a history of vascular disease. †The Adult 
Treatment Panel III (ATP III) of the National Cholesterol Education p rogram in the 
USA. ‡The Fourth Joint Task Force of the European Society of Cardiology (ESC) 
and Other Societies on Cardiovascular Disease Prevention in Clinical Practice and 
the ESC/EAS Guidelines for the management of dyslipidaemias. §The National 
Institute for Health and Clinical Excellence (NICE) in the National Health Service in 
England and Wales.
Table 3: Eligibility of CTT participants without a history of vascular 
disease for statin therapy under existing major guidelines, by estimated 
5-year major vascular event risk
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